title: Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.
abstract: In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL(5)KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-gamma secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.
authors: Department of Infectious Disease Immunology, Statens Serum Institut, Adjuvant Research, 5 Artillerivej, DK-2300 Copenhagen S, Denmark. eag@ssi.dk
authors: Else Marie
authors: EM
authors: Agger
authors: Ida
authors: I
authors: Rosenkrands
authors: Anja Weinreich
authors: AW
authors: Olsen
authors: Graham
authors: G
authors: Hatch
authors: Ann
authors: A
authors: Williams
authors: Constantia
authors: C
authors: Kritsch
authors: Karen
authors: K
authors: Lingnau
authors: Alexander
authors: A
authors: von Gabain
authors: Claire Swetman
authors: CS
authors: Andersen
authors: Karen Smith
authors: KS
authors: Korsholm
authors: Peter
authors: P
authors: Andersen